Solara Active Pharma Q4 Review- Recovering Business Provides Respite: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.Solara Active Pharma Science Ltd. has reported better-than-estimated result in Q4 FY22 led by business recovery, which achieved ~90% of normalised revenue. Revenue, Ebitda profit after tax declined ~19%, ~86% and ~97%, respectively, on a YoY basis. However, sequentially, revenue grew ~260% on an impacted base of Q3 FY22 which was on account of inventory adjustment. Solara Active Pharma announced withdrawal of merger with Aurore Life Sciences Pvt. Ltd. due to subdued performance of both the entities. While we believe near-term performance would remain under pressure due to business volatility, cost inflation and withdrawal of Aurore merger, sharp correction in stock (down 34% from Q3 result and 49% in last six months) has priced in most concerns. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Solara Active Pharma Q4 Review- Recovering Business Provides Respite: ICICI Securities

Solara Active Pharma Q4 Review- Recovering Business Provides Respite: ICICI Securities

Choose a plan